Form 4 for NVCR NovoCure Ltd
Accepted 2025-09-08 00:00:00 ET · period of report 2025-09-05 · accession 0001562180-25-006130 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-08 | 2025-09-05 | NVCR | Cordova Ashley | CEO | P - Purchase | $12.22 | +81.5K | 437.6K | +23% | +$996.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-09-05 | P | A | 81,550 | $12.22 | 437,569 | D | — | — | (F1) On the transaction date, the reporting person purchased 81,550 shares in multiple trades at prices ranging from $12.02 to $12.47. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. |